IGHE and allergic asthma: For example, mAbs like mepolizumab (anti-IL-5), dupilumab (anti-IL-4/IL-13), and omalizumab (anti-IgE) have improved outcomes in patients with eosinophilic and allergic asthma, respectively (Koski and Grzegorczyk, 2020).